论文部分内容阅读
随着免疫细胞生物学及免疫分子生物学的高速发展,细胞介导的过继免疫治疗已成为肿瘤患者放、化疗后辅助治疗的重要手段之一。细胞因子诱导的杀伤细胞治疗是近年来具有代表性的过继免疫治疗方法,研究和应用进展迅速。CIK细胞在体外可以快速扩增,具有高效的非主要组织相容性复合物限制性杀瘤活性,被认为是抗肿瘤过继细胞免疫治疗的新希望。随着细胞操作及基因修饰技术的日益精进,人们正逐渐改进CIK细胞的体外培养和处理方法,以便进一步提高CIK细胞的增殖率及特异杀伤力,使其更好地应用于临床。
With the rapid development of immune cell biology and immune molecular biology, cell-mediated adoptive immunotherapy has become an important means of adjuvant therapy for cancer patients after radiotherapy and chemotherapy. Cytokine-induced killer cell therapy is a representative adoptive immunotherapy in recent years, research and application of rapid progress. CIK cells can be rapidly expanded in vitro, with efficient non-major histocompatibility complex limiting tumor-killing activity, is considered a new hope for anti-tumor adoptive cell immunotherapy. With the improvement of cell manipulation and gene modification technology, people are gradually improving the method of culturing and treating CIK cells in vitro, in order to further improve the proliferation rate and specific lethality of CIK cells so that they can be better applied to clinic.